Literature DB >> 33249783

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer's disease.

Oskar Hansson1,2, Nicholas Cullen2,3, Henrik Zetterberg4,5,6,7, Kaj Blennow4,5, Niklas Mattsson-Carlgren2,3,8.   

Abstract

We examined if plasma phosphorylated tau is associated with neurodegeneration in Alzheimer's disease. We investigated 372 cognitively unimpaired participants, 554 mild cognitive impairment patients, and 141 Alzheimer's disease dementia patients. Tau phosphorylated at threonine 181, regional cortical thickness (using magnetic resonance imaging) and hypometabolism (using fluorodeoxyglucose positron emission tomography) were measured longitudinally. High plasma tau was associated with hypometabolism and cortical atrophy at baseline and over time, and longitudinally increased tau was associated with accelerated atrophy, but these associations were only observed in Aβ-positive participants. Plasma phosphorylated tau may identify and track processes linked to neurodegeneration in Alzheimer's disease.
© 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Entities:  

Year:  2020        PMID： 33249783      PMCID： PMC7818141          DOI： 10.1002/acn3.51253

Source DB:  PubMed          Journal:  Ann Clin Transl Neurol        ISSN： 2328-9503            Impact factor:   4.511


  15 in total

1.  Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.

Authors:  Rawan Tarawneh; Denise Head; Samantha Allison; Virginia Buckles; Anne M Fagan; Jack H Ladenson; John C Morris; David M Holtzman
Journal:  JAMA Neurol       Date:  2015-06       Impact factor: 18.302

2.  Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI.

Authors:  Susan M Landau; Andy Horng; Allison Fero; William J Jagust
Journal:  Neurology       Date:  2016-03-11       Impact factor: 9.910

3.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

4.  Amyloid deposition, hypometabolism, and longitudinal cognitive decline.

Authors:  Susan M Landau; Mark A Mintun; Abhinay D Joshi; Robert A Koeppe; Ronald C Petersen; Paul S Aisen; Michael W Weiner; William J Jagust
Journal:  Ann Neurol       Date:  2012-10       Impact factor: 10.422

5.  The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.

Authors:  Clifford R Jack; Matt A Bernstein; Nick C Fox; Paul Thompson; Gene Alexander; Danielle Harvey; Bret Borowski; Paula J Britson; Jennifer L Whitwell; Chadwick Ward; Anders M Dale; Joel P Felmlee; Jeffrey L Gunter; Derek L G Hill; Ron Killiany; Norbert Schuff; Sabrina Fox-Bosetti; Chen Lin; Colin Studholme; Charles S DeCarli; Gunnar Krueger; Heidi A Ward; Gregory J Metzger; Katherine T Scott; Richard Mallozzi; Daniel Blezek; Joshua Levy; Josef P Debbins; Adam S Fleisher; Marilyn Albert; Robert Green; George Bartzokis; Gary Glover; John Mugler; Michael W Weiner
Journal:  J Magn Reson Imaging       Date:  2008-04       Impact factor: 4.813

6.  Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.

Authors:  Thomas K Karikari; Tharick A Pascoal; Nicholas J Ashton; Shorena Janelidze; Andréa Lessa Benedet; Juan Lantero Rodriguez; Mira Chamoun; Melissa Savard; Min Su Kang; Joseph Therriault; Michael Schöll; Gassan Massarweh; Jean-Paul Soucy; Kina Höglund; Gunnar Brinkmalm; Niklas Mattsson; Sebastian Palmqvist; Serge Gauthier; Erik Stomrud; Henrik Zetterberg; Oskar Hansson; Pedro Rosa-Neto; Kaj Blennow
Journal:  Lancet Neurol       Date:  2020-05       Impact factor: 44.182

7.  Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings.

Authors:  Clifford R Jack; Heather J Wiste; Stephen D Weigand; David S Knopman; Michelle M Mielke; Prashanthi Vemuri; Val Lowe; Matthew L Senjem; Jeffrey L Gunter; Denise Reyes; Mary M Machulda; Rosebud Roberts; Ronald C Petersen
Journal:  Brain       Date:  2015-09-30       Impact factor: 13.501

Review 8.  NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Authors:  Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling
Journal:  Alzheimers Dement       Date:  2018-04       Impact factor: 21.566

9.  Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.

Authors:  Carles Falcon; Alan Tucholka; Gemma C Monté-Rubio; Raffaele Cacciaglia; Grégory Operto; Lorena Rami; Juan Domingo Gispert; José Luis Molinuevo
Journal:  Neuroimage Clin       Date:  2018-04-16       Impact factor: 4.881

10.  Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration.

Authors:  Elisabeth H Thijssen; Renaud La Joie; Amy Wolf; Amelia Strom; Ping Wang; Leonardo Iaccarino; Viktoriya Bourakova; Yann Cobigo; Hilary Heuer; Salvatore Spina; Lawren VandeVrede; Xiyun Chai; Nicholas K Proctor; David C Airey; Sergey Shcherbinin; Cynthia Duggan Evans; John R Sims; Henrik Zetterberg; Kaj Blennow; Anna M Karydas; Charlotte E Teunissen; Joel H Kramer; Lea T Grinberg; William W Seeley; Howie Rosen; Bradley F Boeve; Bruce L Miller; Gil D Rabinovici; Jeffrey L Dage; Julio C Rojas; Adam L Boxer
Journal:  Nat Med       Date:  2020-03-02       Impact factor: 53.440
View more
  6 in total

Review 1.  Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease.

Authors:  Sheila Seleri Assunção; Reisa A Sperling; Craig Ritchie; Diana R Kerwin; Paul S Aisen; Claire Lansdall; Alireza Atri; Jeffrey Cummings
Journal:  Alzheimers Res Ther       Date:  2022-04-19       Impact factor: 8.823

2.  Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer's Disease.

Authors:  Ioanna Tsantzali; Aikaterini Foska; Eleni Sideri; Evdokia Routsi; Effrosyni Tsomaka; Dimitrios K Kitsos; Christina Zompola; Anastasios Bonakis; Sotirios Giannopoulos; Konstantinos I Voumvourakis; Georgios Tsivgoulis; George P Paraskevas
Journal:  Biomedicines       Date:  2022-08-03

3.  Self- and Partner-Reported Subjective Memory Complaints: Association with Objective Cognitive Impairment and Risk of Decline.

Authors:  Leah Zuroff; Laura Em Wisse; Trevor Glenn; Sharon X Xie; Ilya M Nasrallah; Mohamad Habes; Jacob Dubroff; Robin de Flores; Long Xie; Paul Yushkevich; Jimit Doshi; Christos Davatsikos; Leslie M Shaw; Thomas F Tropea; Alice S Chen-Plotkin; David A Wolk; Sandhitsu Das; Dawn Mechanic-Hamilton
Journal:  J Alzheimers Dis Rep       Date:  2022-07-22

4.  Association of plasma P-tau181 with memory decline in non-demented adults.

Authors:  Joseph Therriault; Andrea L Benedet; Tharick A Pascoal; Firoza Z Lussier; Cecile Tissot; Thomas K Karikari; Nicholas J Ashton; Mira Chamoun; Gleb Bezgin; Sulantha Mathotaarachchi; Serge Gauthier; Paramita Saha-Chaudhuri; Henrik Zetterberg; Kaj Blennow; Pedro Rosa-Neto
Journal:  Brain Commun       Date:  2021-06-14

5.  Identification of plasma proteins relating to brain neurodegeneration and vascular pathology in cognitively normal individuals.

Authors:  Liu Shi; Colin R Buchanan; Simon R Cox; Robert F Hillary; Riccardo E Marioni; Archie Campbell; Caroline Hayward; Aleks Stolicyn; Heather C Whalley; Mathew A Harris; Jennifer Waymont; Gordon Waiter; Ellen Backhouse; Joanna M Wardlaw; Douglas Steele; Andrew Mcintosh; Simon Lovestone; Noel J Buckley; Alejo J Nevado-Holgado
Journal:  Alzheimers Dement (Amst)       Date:  2021-09-27

6.  Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects.

Authors:  Joana B Pereira; Shorena Janelidze; Erik Stomrud; Sebastian Palmqvist; Danielle van Westen; Jeffrey L Dage; Niklas Mattsson-Carlgren; Oskar Hansson
Journal:  Brain       Date:  2021-10-22       Impact factor: 13.501
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.